var data={"title":"Magnesium hydroxide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Magnesium hydroxide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6497?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=magnesium-hydroxide-drug-information\" class=\"drug drug_general\">see &quot;Magnesium hydroxide: Drug information&quot;</a> and <a href=\"topic.htm?path=magnesium-hydroxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Magnesium hydroxide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190917\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dulcolax Milk of Magnesia [OTC];</li>\n      <li>Milk of Magnesia Concentrate [OTC];</li>\n      <li>Milk of Magnesia [OTC];</li>\n      <li>Pedia-Lax [OTC];</li>\n      <li>Phillips [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023043\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antacid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Laxative, Osmotic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023064\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=magnesium-hydroxide-drug-information\" class=\"drug drug_general\">see &quot;Magnesium hydroxide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose expressed as mg of magnesium hydroxide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antacid:</b> Oral: Children &ge;12 years and Adolescents (Phillips 311 mg  chewable tablet): 2 to 4 tablets every 4 hours up to 4 times per day.  Do not exceed 4 doses in 24 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation, chronic:</b> Oral: Infants, Children, and Adolescents: Limited data available: 80 to 240 mg/kg/day divided once or twice daily (Wyllie 2011);  usual adult dose is 2,400 to 4,800 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constipation, occasional:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;6 years: 400 to 1,200 mg/day in single or divided doses. Maximum daily dose: 1,200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to &lt;12 years: 1,200 to 2,400 mg/day in single or divided doses. Maximum daily dose: 2,400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 2,400 to 4,800 mg/day in single or divided doses. Maximum daily dose: 4,800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fecal impaction, slow disimpaction:</b> Limited data available: Oral: Children and Adolescents: 160 mg/kg twice daily for 7 days (Pashankar 2005; Wyllie 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Antacid:</b> OTC labeling: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Liquid:</i> Magnesium hydroxide 400 mg per 5 mL: 5 to 15 mL as needed up to 4 times/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Tablet:</i> Magnesium hydroxide 311 mg per tablet: 2 to 4 tablets every 4 hours up to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Laxative:</b> OTC labeling: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Liquid: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Magnesium hydroxide 400 mg per 5 mL: 30 to 60 mL/day once daily at bedtime or in divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Magnesium hydroxide 800 mg per 5 mL: 15 to 30 mL/day once daily at bedtime or in divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Tablet:</i> Magnesium hydroxide 311 mg/tablet: 8 tablets/day once daily at bedtime or in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a CrCl &lt;30 mL/minute receiving magnesium should have serum magnesium levels monitored. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190904\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dulcolax Milk of Magnesia: 400 mg/5 mL (355 mL) [sugar free; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dulcolax Milk of Magnesia: 400 mg/5 mL (355 mL) [sugar free; contains saccharin sodium; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 400 mg/5 mL (355 mL, 480 mL); 1200 mg/15 mL (355 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 1200 mg/15 mL (355 mL [DSC]) [mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 7.75% (360 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 7.75% (355 mL, 473 mL) [mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 7.75% (30 mL) [spearmint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 400 mg/5mL (473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 1200 mg/15 mL (355 mL) [gluten free, stimulant free, sugar free; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 1200 mg/15 mL (355 mL) [gluten free, stimulant free, sugar free; contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 400 mg/5 mL (355 mL, 473 mL) [low sodium, sugar free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 400 mg/5 mL (355 mL, 473 mL, 769 mL [DSC]); 1200 mg/15 mL (355 mL) [stimulant free, sugar free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 1200 mg/15 mL (355 mL) [stimulant free, sugar free; contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia: 400 mg/5 mL (473 mL); 1200 mg/15 mL (355 mL [DSC]) [sugar free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia Concentrate: 2400 mg/10 mL (100 mL, 400 mL) [lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Milk of Magnesia Concentrate: 2400 mg/10 mL (10 mL) [contains methylparaben, propylene glycol, propylparaben, saccharin sodium; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pedia-Lax: 400 mg [scored; stimulant free; contains fd&amp;c red #40 aluminum lake; watermelon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Phillips: 311 mg [DSC] [mint flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190891\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023069\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Liquid doses may be diluted with a small amount of water prior to administration. All doses should be followed by 8 ounces of water in patients &ge;2 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48961602\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Keep tightly closed. Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from freezing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1023044\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Relief of occasional constipation (OTC products: FDA approved in ages &ge;2 years and adults); relief of heartburn, sour stomach, acid indigestion, and upset stomach associated with these conditions (OTC products: Phillips chewable tablet: FDA approved in ages &ge;12 years and adults). <b>Note:</b> Refer to product labeling for specific information on uses and approval in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190911\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any ingredient</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190895\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a health care provider in patients with kidney dysfunction, a magnesium-restricted diet, stomach pain/nausea/vomiting, or with a sudden change in bowel habits which persist for &gt;2 weeks. Patients should stop use as a laxative and notify health care provider of any rectal bleeding, if bowel movement does not occur after using product, or if use is needed for &gt;1 week. Stop use as an antacid and notify health care provider if you have taken the maximum dose for &gt;2 weeks. Not for OTC use in children &lt;2 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017103\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or underdosing.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299634\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221407\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12980&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib from the administration of any antacids by at least 2 hours in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Antacids may decrease the absorption of Allopurinol. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antacids may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Antacids may decrease the absorption of Atazanavir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Antacids may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered while fasting at least 2 hours before antacids. Giving with or 2 hours after antacids is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Antacids may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Antacids may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Antacids may decrease the absorption of Dasatinib. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: Antacids may decrease the absorption of Diacerein. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine.  Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Antacids may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Antacids may diminish the therapeutic effect of Methenamine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiSOPROStol: Antacids may enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption.  Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of antacids in combination with pazopanib whenever possible.  Separate doses by several hours if antacid treatment is considered necessary.  The impact of dose separation has not been investigated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration.  Separating administer of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Antacids may decrease the excretion of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Antacids may decrease the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Antacids may decrease the absorption of Quinolones. Of concern only with oral administration of quinolones.  Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14081348\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Idama 1998; Osada 2002). The American Gastroenterological Association considers the use of magnesium containing antacids to be low risk in pregnancy (Mahadevan 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190894\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity; reacts with hydrochloric acid in stomach to form magnesium chloride</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F190910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Laxative: 30 minutes to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Up to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (up to 30% as absorbed magnesium ions); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6855871\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Pedia-Lax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (30): $5.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038670\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antagel M (HU);</li>\n      <li>Chlorumagene (FR);</li>\n      <li>Deopens (ZA);</li>\n      <li>Emgesan (FI, SE);</li>\n      <li>Grays Milk of Magnesia (ZW);</li>\n      <li>Laxasium (ID);</li>\n      <li>Laxomag (AE, ET);</li>\n      <li>Leche De Magnesia (CO, EC, PE);</li>\n      <li>Magmil (KR);</li>\n      <li>Magnason (BD);</li>\n      <li>Magnesia san Pelligrino (IT);</li>\n      <li>Marogel (KR);</li>\n      <li>Milk of Magnesia (BD, IE, IL, PL, QA, SA);</li>\n      <li>Milmag (PL);</li>\n      <li>Phillips Milk of Magnesia (MT);</li>\n      <li>Premamilk (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 19th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idama TO and Lindow SW, &quot;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&quot; <i>Br J Obstet Gynaecol</i>, 1998, 105(3):260-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/9532984/pubmed\" target=\"_blank\" id=\"9532984\">9532984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute of Medicine (IOM), <i>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride</i>, National Academy of Sciences, Washington, DC, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U and Kane S, &quot;American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,&quot; <i>Gastroenterology</i>, 2006, 131(1):278-82. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/16831610/pubmed\" target=\"_blank\" id=\"16831610\">16831610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milk of Magnesia (magnesium hydroxide) [prescribing information]. Bayer Healthcare.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osada H, Watanabe Y, Nishimura Y, et al, &quot;Profile of Trace Element Concentrations in the Feto-placental Unit in Relation to Fetal Growth,&quot; <i>Acta Obstet Gynecol Scand</i>, 2002, 81(10):931-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/12366483/pubmed\" target=\"_blank\" id=\"12366483\">12366483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS. Childhood constipation: evaluation and management.<i> Clin Colon Rectal Surg</i>. 2005;18(2):120-127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/20011352 /pubmed\" target=\"_blank\" id=\"20011352 \">20011352 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pedia-Lax (magnesium hydroxide) [prescribing information]. Lynchburg, VA: C.B. Fleet Company Inc.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips' Chewable Tablets (magnesium hydroxide) [prescribing information]. Bayer Healthcare; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips' Concentrated Milk of Magnesia (magnesium hydroxide) [prescribing information].  Bayer Healthcare; November 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips' Milk of Magnesia Original (magnesium hydroxide) [prescribing information]. Bayer Healthcare; October 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/magnesium-hydroxide-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wyllie R, Hyams JS, eds. <i>Pediatric Gastrointestinal and Liver Disease: Expert Consult - Online and Print</i>. 4th ed. Philadelphia, PA: Saunders; January 2011.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12980 Version 157.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F190917\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1023043\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1023064\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F190904\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F190891\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1023069\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F48961602\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1023044\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F190911\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F190895\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017103\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299634\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221407\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14081348\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F190894\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F190910\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6855871\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038670\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12980|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=magnesium-hydroxide-drug-information\" class=\"drug drug_general\">Magnesium hydroxide: Drug information</a></li><li><a href=\"topic.htm?path=magnesium-hydroxide-patient-drug-information\" class=\"drug drug_patient\">Magnesium hydroxide: Patient drug information</a></li></ul></div></div>","javascript":null}